Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.48 |
| ▸ | NOS3 | P29474 | 5/20 | 0.48 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698670 | 1.00 | NOS1 (0.48) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4698667 | 1.00 | NOS1 (0.48) | NOS1NOS3NOS2QRFPR | |
| Hydrochloric Acid SCHEMBL5639556 | 0.99 | NOS1 (0.47) | NOS1NOS3NOS2QRFPR | |
| Hydrochloric Acid SCHEMBL5639555 | 0.99 | NOS1 (0.47) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4701628 | 0.90 | NOS1 (0.50) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4701645 | 0.90 | NOS1 (0.50) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4701638 | 0.90 | NOS1 (0.50) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL5643297 | 0.90 | NOS1 (0.53) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL5640927 | 0.89 | NOS1 (0.49) | NOS1NOS3NOS2QRFPR | |
| Hydrochloric Acid SCHEMBL5640935 | 0.89 | NOS1 (0.49) | NOS1NOS3NOS2QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | claimed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | claimed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | claimed |
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | disclosed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | OPRL1, CBR3, SCN5A | NOS1 680/4885NOS3 207/4885NOS2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.